Sonlicromanol

DRUG4 trials

Sponsors

Amsterdam UMC Stichting, Khondrion BV, Michele van Vugt

Conditions

MELASMaternally Inherited Diabetes and Deafness (MIDD)Mitochondrial DNA tRNALeu(UUR) m.3243A<G MutationMitochondrial DiseasesMitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)Post COVID ConditionSubacute Necrotizing Encephalomyelopathylong COVID

Phase 2

The KHENERGYC Study

SuspendedNCT04846036

Khondrion BVMELAS, Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation +1

Start: 2021-02-01End: 2025-12-01Target: 24Updated: 2025-01-10

SON4PEM study: Sonlicromanol in post-COVID: A randomized, double-blind, placebo-controlled, phase II trial

RecruitingCTIS2025-521866-92-01

Amsterdam UMC Stichtinglong COVID

Start: 2025-12-12Target: 80Updated: 2025-12-02

Sonlicromanol in Post-COVID

RecruitingNCT07298005

Michele van VugtPost COVID Condition

Start: 2026-04-03End: 2027-03-01Target: 80Updated: 2026-08-18

Phase 3

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

RecruitingNCT06451757

Khondrion BVMaternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation +1

Start: 2026-04-14End: 2028-09-01Target: 220Updated: 2026-06-29

Related Papers

A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms ("KHENERGYC").

2022-04-279 citations